UBS upgraded ResMed (RMD) to Buy from Neutral with a price target of $290, up from $255. The firm thinks consensus is too cautious in the ...

Apple (AAPL) reported December quarter revenue above expectations driven by modestly better iPhone revenue, and provided limited March ...

Authorities in many countries are scrambling for solutions to mounting shortages of medicine. Will any of them work?